Multiple Myeloma

Publisher Website
Google Scholar
Abstract
A mouse myeloma tumor (X5563) produces a plasmocytic tumor, bone marrow and spleen involvement, and a typical myeloma electrophoretic pattern at 60 days after inoculation. Resection of the mass of tumor causes a decrease in the myeloma protein which gradually returns, suggesting quantitative correlation between amount of plasmocytoma and M-protein. Cyclosphosphamide (Cytoxan, Protoxan, Endoxan)* reduces tumor size and M-protein in the experimental animals. Patients ill with myeloma have shown varying remission following a course of cyclophosphamide. The clinical remissions have been associated with improved renal and marrow function and decrease of urine and serum myeloma proteins. Thirty-one patients with symptomatic myeloma have been treated with oral daily doses of cyclophosphamide. Nineteen patients were considered evaluable as they received therapy for more than 60 days. Sixteen of these patients developed partial or good remission and have shown objective changes in protein bone marrow or peripheral blood values.